Surrozen, Inc./DE
No enriched coverage for $SRZN in the last 7 days.
No SEC Form 4 filings for $SRZN in the last 30 days.
See all $SRZN insider activity →Guggenheim analyst Yatin Suneja named Surrozen Inc (SRZN) as the top biotechnology stock pick, citing progress in eye disease treatments. The company submitted an Investigational New Drug application for SZN-8141, triggering $98.4 million in funding. Guggenheim expects smooth IND clearance and clinical study initiations by late 2026. The analyst also noted upcoming Merck study results that could impact the sector.
Investing.com reports Guggenheim named Surrozen Inc. (SRZN) its top biotech stock pick, reiterating a Buy rating. The focus is the Phase IIb/III BRUNELLO readout, with primary completion expected in September and full data potentially in October. Guggenheim cites potential upside of 2 to 3 times current levels and highlights SRZN-8141/8143 and upcoming DUET timing.
Surrozen, Inc./DE (SRZN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update Planned IND submission for SZN-8141 in diabetic macular edema by the end of the third quarter of 2026 Expect to initiate SZN-8141 Phase 1b/2a study, DUET, by year-end 2026 with initia
Recent SRZN coverage spans financial news, sector analysis and earnings.
Positive regulatory filing and capital infusion may boost SRZN's near-term share price.
Near-term catalyst is the Phase IIb/III BRUNELLO readout (primary completion expected in September, potential AAO presentation in October), with additional pipeline milestones (SRZN-8141 IND by end of Q3 2026).
Near-term trading focus is on the DUET Phase 1b/2a initiation timeline, IND submission progress, and PTAB denial of Merck’s post-grant review petition supporting IP risk reduction.
A large sale by an insider can pressure sentiment, though the disgorgement note suggests compliance mechanics.
The filing is a routine insider-sale disclosure with no stated 10b5-1 plan, but it does not by itself confirm negative fundamentals.
AlphAI scores every news story that mentions SRZN with an AI model for sentiment and relevance, and aggregates insider trades from Surrozen, Inc./DE's SEC EDGAR Form 4 filings. Figures refresh continuously.
Guggenheim analyst Yatin Suneja named Surrozen Inc (SRZN) as the top biotechnology stock pick, citing progress in eye disease treatments. The company submitted an Investigational New Drug application for SZN-8141, triggering $98.4 million in funding. Guggenheim expects smooth IND clearance and clinical study initiations by late 2026. The analyst also noted upcoming Merck study results that could impact the sector.
2 min readInvesting.com reports Guggenheim named Surrozen Inc. (SRZN) its top biotech stock pick, reiterating a Buy rating. The focus is the Phase IIb/III BRUNELLO readout, with primary completion expected in September and full data potentially in October. Guggenheim cites potential upside of 2 to 3 times current levels and highlights SRZN-8141/8143 and upcoming DUET timing.
3 min readSurrozen, Inc./DE (SRZN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update Planned IND submission for SZN-8141 in diabetic macular edema by the end of the third quarter of 2026 Expect to initiate SZN-8141 Phase 1b/2a study, DUET, by year-end 2026 with initia
5 min readInvesting.com reported Friday’s notable U.S. insider transactions. ClearSign (CLIR) director bought 500,000 shares for $1.77M at $3.54. Five Star Bancorp (FSBC) director bought 96,591 shares for $4.25M at $44. Rhinebeck Bancorp (RBKB) directors and CEO bought shares totaling about $596k. Levi (LEVI) CFO sold 98,144 shares for $2.38M. State Street (STT) sold 14,553 shares for $2.68M; Travelers (TRV) sold 6,000 for $2.2M; Domino’s (DPZ) sold about $4.0M.
4 min readTCG Crossover GP II, LLC sold 325,000 indirectly-held shares of Surrozen, Inc./DE (SRZN) at $21.25 ($6.91M total) across 2 trades on 2026-07-22.
2 min readSurrozen (NASDAQ:SRZN) presented preclinical data on SZN-8141, an antibody intended to activate Wnt signaling while inhibiting VEGF, and highlighted an IND filing planned for the second half of this year. Company speakers said combined Wnt agonism and VEGF inhibition improved efficacy in mouse models and may target retinal non-perfusion. The article also discussed SZN-8143 and IL-6’s role in retinal disease.
6 min readSurrozen to Present at Two Upcoming Healthcare Investor Conferences - Piper Sandler and ...
2 min readSurrozen Reports Inducement Grant Under Nasdaq Listing Rule ...
2 min readSOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 ( GLOBE NEWSWIRE ) -- Surrozen, Inc. ( "Surrozen" or the "Company" ) ( Nasdaq: SRZN ) , a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye ...
3 min readSurrozen Reports Inducement Grants Under Nasdaq Listing Rule ...
2 min read